September 24 is World Cancer Research Day, dedicated to supporting the research and innovations that improve outcomes for cancer patients across the globe. So far this year, the FDA has approved ten novel anticancer therapies, for breast cancer, multiple myeloma, acute myeloid leukemia and more. 

The pairing of Merck’s blockbuster immunotherapy Keytruda and Eisai’s Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well.

AstraZeneca said on its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer.

While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.” 

Beigene said on Tuesday it would regain rights to develop and sell its cancer drug globally from Swiss drugmaker Novartis after the companies mutually decided to end their licensing deal.

The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.

Following a regulatory victory for Jemperli in endometrial cancer last month, GSK continues its oncology winning streak with an FDA approval for momelotinib in myelofibrosis with anemia.

Last November Blenrep failed to meet the main goal in a late-stage study that was designed to show it was better than an existing treatment on the market, leading GSK to stop selling the drug in the United States.

The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition.

The company will save about $130 million in 2024-25 as it eliminates 176 roles.